Niagen IV vs. NAD+ IV: What’s the Difference?

What is NAD+?

NAD+ stands for nicotinamide adenine dinucleotide.

It is a coenzyme found throughout the body and is involved in cellular energy metabolism, signaling, and other normal cellular processes.

That biology has driven interest in ways to influence NAD-related pathways, including NAD+ IV therapy and precursors such as nicotinamide riboside.

But the biology of NAD+ is much better established than the clinical benefits of IV NAD+ therapy itself.

Research into intravenous NAD+ remains limited, particularly when the question is whether treatment improves outcomes such as energy, cognition, recovery, or healthy aging.

NAD+ Support: Potential Benefits and Clinical Review

What is Niagen IV?

Niagen IV contains pharmaceutical-grade nicotinamide riboside chloride.

Nicotinamide riboside is a form of vitamin B3 and an NAD+ precursor. Instead of supplying NAD+ directly, it gives the body material it can use in NAD-producing pathways.

That makes Niagen IV biologically different from NAD+ IV even though both are discussed within the broader NAD-support category.

The important distinction is therefore:

NAD+ IV → delivers NAD+

Niagen IV → delivers nicotinamide riboside, which the body can use to produce NAD+

That difference is real. The question of whether it leads to meaningfully different long-term health outcomes is still being studied.

What have head-to-head studies found?

Human research directly comparing intravenous nicotinamide riboside with NAD+ IV is still small.

A randomized, double-blind pilot study compared a single 500 mg dose of intravenous nicotinamide riboside with 500 mg NAD+ IV, oral NR, and saline in generally healthy adults.

The study evaluated blood NAD+ response, safety, and tolerability. It reported that IV NR increased whole-blood NAD+ and was generally better tolerated during administration than NAD+ IV.

That study remains a preprint, meaning it has not completed peer review.

A second study published in Frontiers in Aging in 2026 reviewed real-world records from a small group receiving four consecutive days of either 500 mg NAD+ IV or 500 mg intravenous NR.

In that study:

• NR infusions averaged about 37 minutes
• NAD+ infusions averaged about 97 minutes
• the NAD+ group reported more moderate-to-severe infusion symptoms
• the NR group generally reported milder infusion-related symptoms

The study was small—six people received NAD+ and eight received NR—and it was retrospective rather than a randomized trial. The authors described the findings as preliminary and called for larger, controlled studies.

So the reasonable conclusion is not that Niagen IV has been proven “better.”

The evidence currently supports a narrower statement: intravenous NR may allow a shorter and more tolerable infusion experience than NAD+ IV in the small studies performed so far.

Does a shorter infusion mean better results?

No.

Infusion time and treatment outcome are different questions.

A treatment can be easier or faster to administer without producing superior long-term health results.

The available head-to-head research has focused mainly on NAD+ response, infusion experience, tolerability, and short-term safety—not whether one therapy produces better energy, cognition, athletic recovery, longevity, or disease outcomes.

That distinction matters because NAD-related therapies are often marketed far beyond what the human clinical evidence currently supports.

A 2026 systematic review of NAD+ supplementation and wellness research found much stronger human evidence that oral NAD+ precursors can raise circulating NAD+ than evidence supporting specific clinical benefits from intravenous NAD+ therapy. The review described IV NAD+ evidence as limited.

What about side effects and tolerability?

Both NAD+ IV and Niagen IV should be administered with clinical review and monitoring.

NAD+ IV is often infused slowly because some people experience uncomfortable symptoms when the infusion rate is increased.

In the small comparative studies performed so far, intravenous NR was generally associated with fewer or milder infusion-related symptoms and shorter administration times.

That is useful information when comparing the visit experience.

It should not be turned into a blanket statement that one therapy is safer for every person.

Medical history, medications, pregnancy status, current symptoms, previous reactions, and the reason for treatment still matter.

What about NAD+ injections, Niagen shots, and oral supplements?

Those are different questions from Niagen IV versus NAD+ IV.

Injection-based and oral options differ in route, frequency, clinical oversight, convenience, and available research.

If you are comparing the broader delivery formats rather than just the two IV options, see:

NAD Injections vs. IV Therapy vs. Oral Supplements

That article remains the deeper owner of the delivery-format question.

How should I decide between Niagen IV and NAD+ IV?

The decision should start with practical and clinical questions rather than claims that one product is universally superior.

Consider:

• Are you specifically looking at an NAD+ IV or an NR-based IV?
• How much time can you reasonably devote to the infusion?
• Have you previously had difficulty tolerating NAD+ IV?
• What goal are you expecting the treatment to support?
• Is that expectation supported by current evidence?
• Does your health history or medication list affect the decision?
• Has a clinician reviewed which option is appropriate for you?

Neither product should be selected simply because it sounds newer, stronger, or more advanced.

At purelyIV, current service options, pricing, available doses, visit timing, and booking details remain on the dedicated treatment pages:

NAD+ IV Therapy

Niagen IV

Bottom line

Niagen IV and NAD+ IV both sit within the broader NAD-support conversation, but they work through different starting molecules.

NAD+ IV delivers NAD+ directly. Niagen IV delivers nicotinamide riboside, a precursor the body can use to produce NAD+.

Early human comparisons suggest that intravenous NR can be administered faster and may be easier to tolerate during the infusion than NAD+ IV. Those findings are useful, but the studies remain small and do not establish that Niagen IV produces superior long-term health outcomes.

The right choice depends on the treatment being considered, the available evidence, the visit experience, your health history, and clinician review.